S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Forecast, Price & News

$1.11
+0.03 (+2.78%)
(As of 05/20/2022 03:49 PM ET)
Add
Compare
Today's Range
$1.05
$1.11
50-Day Range
$1.02
$2.34
52-Week Range
$1.02
$5.07
Volume
110 shs
Average Volume
24,812 shs
Market Capitalization
$9.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.58
30 days | 90 days | 365 days | Advanced Chart
Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Benitec Biopharma logo

About Benitec Biopharma

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Headlines

Benitec Biopharma Discloses Q2 2022 Financial Results
/C O R R E C T I O N from Source -- Norra Metals Corp./
Benitec Biopharma Discloses Q1 2022 Financial Results
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTC
Employees
14
Year Founded
N/A

Sales & Book Value

Annual Sales
$60 thousand
Book Value
$0.92 per share

Profitability

Net Income
$-13.88 million
Pretax Margin
-22,858.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
7,960,000
Market Cap
$9.07 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/23/2022
Fiscal Year End
6/30/2022
Next Earnings (Estimated)
9/19/2022

MarketRank

Overall MarketRank

1.68 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Benitec Biopharma (NASDAQ:BNTC) Frequently Asked Questions

Is Benitec Biopharma a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Benitec Biopharma stock.
View analyst ratings for Benitec Biopharma
or view top-rated stocks.

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 4,800 shares, an increase of 166.7% from the April 15th total of 1,800 shares. Based on an average daily volume of 23,200 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company's shares are sold short.
View Benitec Biopharma's Short Interest
.

When is Benitec Biopharma's next earnings date?

Benitec Biopharma is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our earnings forecast for Benitec Biopharma
.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) released its quarterly earnings results on Monday, May, 16th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.04.
View Benitec Biopharma's earnings history
.

What price target have analysts set for BNTC?

1 Wall Street analysts have issued 12-month target prices for Benitec Biopharma's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Benitec Biopharma's share price to reach $10.00 in the next year. This suggests a possible upside of 800.9% from the stock's current price.
View analysts' price targets for Benitec Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Benitec Biopharma's key executives?
Benitec Biopharma's management team includes the following people:
  • Dr. Jerel A. Banks M.D., Ph.D., CEO & Exec. Chairman (Age 47, Pay $697.69k)
  • Ms. Megan Joan Boston BComm, CA, Dip., GAICD, Exec. Director (Age 50, Pay $401.7k)
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist
  • Dr. Craig Lewis, Chief Medical Adviser
  • Dr. Claudia Kloth, Sr. VP of Manufacturing
What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Benitec Biopharma's stock symbol?

Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Silverarc Capital Management LLC (6.03%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends for Benitec Biopharma
.

Which major investors are selling Benitec Biopharma stock?

BNTC stock was sold by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC.
View insider buying and selling activity for Benitec Biopharma
or view top insider-selling stocks.

Which major investors are buying Benitec Biopharma stock?

BNTC stock was bought by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
View insider buying and selling activity for Benitec Biopharma
or or view top insider-buying stocks.

How do I buy shares of Benitec Biopharma?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Benitec Biopharma's stock price today?

One share of BNTC stock can currently be purchased for approximately $1.11.

How much money does Benitec Biopharma make?

Benitec Biopharma has a market capitalization of $9.07 million and generates $60 thousand in revenue each year. The biotechnology company earns $-13.88 million in net income (profit) each year or ($179.010010) on an earnings per share basis.

How many employees does Benitec Biopharma have?

Benitec Biopharma employs 14 workers across the globe.

What is Benitec Biopharma's official website?

The official website for Benitec Biopharma is www.benitec.com.

How can I contact Benitec Biopharma?

Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company can be reached via phone at 510-780-0819, via email at [email protected], or via fax at 61 (0)3 9966-9923.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.